clinical trial · NCT07132112
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
Grit Biotechnology·early phase1·recruiting·n = 30
Auto Immune DiseaseGT719 Injection
brief summary
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune disease. A total of 30 subjects will be enrolled in this study.
started
Oct 28, 2025
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Apr 16, 2026
official title
A Single-arm, Open-label Clinical Study of GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol